BioLife SolutionsBLFS +4.25%72 Net Current Asset Value is $2.14 as of Mar. 2026, which is 85% below its 10-year median of 14.55. GuruFocus rates BLFS with a GF Score™ of 72/100 and a GF Value™ of $28.57 (Fairly Valued). The stock has 5 warning signs investors should review. Among 566 Medical Devices & Instruments companies, BioLife Solutions ranks worse than 79.51% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
BioLife Solutions's net current asset value per share for the quarter that ended in Mar. 2026 was $2.14.
The historical rank and industry rank for BioLife Solutions's Net Current Asset Value or its related term are showing as below:
BLFS'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.82 Med: 14.55 Max: 61.33
Current: 13.38
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of BioLife Solutions was 61.33. The lowest was 7.82. And the median was 14.55.
BLFS's Price-to-Net-Current-Asset-Value is ranked worse than 79.51% of 566
companies
in the Medical Devices & Instruments industry
Industry Median: 4.89
vs BLFS: 13.38
BioLife Solutions (NAS:BLFS) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
BioLife Solutions Net Current Asset Value Related Terms
BioLife Solutions Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for BioLife Solutions's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLFS vs KMTS, AZTA, ATRC: Net Current Asset Value Comparison
For the Medical Instruments & Supplies subindustry, BioLife Solutions's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLife Solutions Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where BioLife Solutions's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $2.14 mean?
BioLife Solutions (BLFS) has a Net Current Asset Value of $2.14 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioLife Solutions and its competitors. This is 85% below median its historical median of 14.55. Over the past decade, BioLife Solutions' Net Current Asset Value has ranged from 7.82 to 61.33. According to the industry distribution chart, BioLife Solutions ranks #450 out of 566 companies in the Medical Devices & Instruments industry, placing it in the top 79.5%.
Is BioLife Solutions' Net Current Asset Value too high?
BioLife Solutions' current Net Current Asset Value of $2.14 is 85% below median its 10-year median of 14.55. Over the past 10 years, this metric has ranged from a low of 7.82 to a high of 61.33. The Medical Devices & Instruments industry median Net Current Asset Value is 4.89. BioLife Solutions' value of $2.14 is 56.2% below this industry median. Based on the distribution chart, BioLife Solutions ranks #450 out of 566 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, BioLife Solutions has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioLife Solutions' Net Current Asset Value compare to KMTS and AZTA?
According to the Medical Devices & Instruments industry distribution chart, BioLife Solutions ranks #450 out of 566 companies for Net Current Asset Value. This places BioLife Solutions in the lower half of its industry. The industry median Net Current Asset Value is 4.89. BioLife Solutions' value of $2.14 is 56.2% below this benchmark. Historically, BioLife Solutions' own Net Current Asset Value has ranged from 7.82 to 61.33 over the past decade. While the company's 10-year median is 14.55 vs. the industry median of 4.89, BioLife Solutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.89, based on 566 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioLife Solutions's current Net Current Asset Value of $2.14 is 56.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on BioLife Solutions and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioLife Solutions's current Net Current Asset Value is $2.14, which is 85% below median its own 10-year median of 14.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLife Solutions stock overvalued right now?
Based on GuruFocus' analysis, BioLife Solutions (BLFS) is currently considered Fairly Valued. The stock's GF Value™ is $28.57, compared to a current price of $28.64 — trading 0.2% above its estimated fair value. The current Net Current Asset Value is $2.14, which is 85% below median its 10-year median of 14.55 and 56.2% below the Medical Devices & Instruments industry median of 4.89. BioLife Solutions' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For BioLife Solutions (BLFS), the current Net Current Asset Value is $2.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioLife Solutions (BLFS) Overvalued in 2026?
Based on GuruFocus' analysis, BioLife Solutions stock appears to be overvalued.
The current stock price of $28.64 is trading 0.2% above its estimated GF Value™ of $28.57.
GuruFocus considers BioLife Solutions to be Fairly Valued.
Key valuation signals for BLFS:
Net Current Asset Value: $2.14 (85% below median its 10-year median of 14.55)
GF Value™: $28.57 vs. price of $28.64 (0.2% above fair value)
Industry Position: 56.2% below the Medical Devices & Instruments median (#450 of 566)
No single metric tells the full story. See the BLFS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
72GF Score
Get the complete analysis for BLFS
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLFS has been successfully added to your 
